Arcus Biosciences (NYSE:RCUS) Rating Reiterated by Cantor Fitzgerald

Arcus Biosciences (NYSE:RCUS)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports.

RCUS has been the topic of a number of other research reports. Wedbush restated an “outperform” rating and issued a $30.00 price objective on shares of Arcus Biosciences in a report on Thursday. Truist Financial cut their price target on shares of Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, June 24th. Barclays decreased their price objective on shares of Arcus Biosciences from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, July 8th. Finally, Evercore ISI upgraded Arcus Biosciences to a “strong-buy” rating in a report on Friday, August 9th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $35.71.

Arcus Biosciences Stock Up 8.8 %

Arcus Biosciences stock opened at $16.65 on Thursday. Arcus Biosciences has a 12 month low of $12.95 and a 12 month high of $20.31. The stock has a market cap of $1.52 billion, a P/E ratio of -5.35 and a beta of 0.90. The company’s fifty day simple moving average is $16.15 and its 200-day simple moving average is $16.05.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, meeting analysts’ consensus estimates of ($1.02). Arcus Biosciences had a negative return on equity of 42.86% and a negative net margin of 100.81%. The firm had revenue of $39.00 million for the quarter, compared to the consensus estimate of $26.24 million. During the same quarter in the previous year, the company posted ($1.04) earnings per share. The business’s quarterly revenue was up 34.5% compared to the same quarter last year. On average, equities research analysts expect that Arcus Biosciences will post -3.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of RCUS. GAMMA Investing LLC grew its position in shares of Arcus Biosciences by 51.6% in the first quarter. GAMMA Investing LLC now owns 2,427 shares of the company’s stock valued at $46,000 after purchasing an additional 826 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Arcus Biosciences in the 1st quarter valued at approximately $59,000. Innealta Capital LLC bought a new position in Arcus Biosciences in the 2nd quarter worth approximately $66,000. Point72 DIFC Ltd acquired a new position in shares of Arcus Biosciences during the second quarter worth approximately $83,000. Finally, ProShare Advisors LLC boosted its position in shares of Arcus Biosciences by 7.4% in the first quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock valued at $205,000 after acquiring an additional 746 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.